Adial Pharmaceuticals, Inc. Cash and Restricted Cash
Adial Pharmaceuticals, Inc. (ADIL) had Cash and Restricted Cash of $28.71 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28.71M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.58M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.88M; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed $5.88M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.61M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $28.71M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $4.58M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $5.88M 10-Q · filed 2026-08-14 | $5.88M 10-K · filed 2026-03-05 |
| 2025-09-30 | $4.61M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $5.92M 10-Q · filed 2026-08-14 | $5.91M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.37M 10-Q · filed 2026-05-08 | |
| 2024-12-31 | $3.75M 10-Q · filed 2026-08-14 | $3.75M 10-K · filed 2025-03-04 |
| 2024-09-30 | $5.20M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $3.29M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $5.03M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $2.83M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $315.88K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.22M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $2.31M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $4.00M 10-K · filed 2025-03-04 | |
| 2022-09-30 | $5.75M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $9.16M 10-Q/A · filed 2023-10-30 | |
| 2022-03-31 | $12.69M 10-Q · filed 2023-05-12 | |
| 2021-12-31 | $6.06M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |